Table 1.
Analysis of survival and R0 status with neoadjuvant treatments according to updated studies and reviews.
| JSAP-05 [24] | Tajima [20] | Michelakos [27] | PREOPANC 1 [28] | Jassen [25] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type of pz (n) | RPC, BRPC (182) | RPC, BRPC (180) | RPC | BRCP (69), LAPC (71) | BRCP (246) | BRCP (283) | LAPC (315) | |||
| Regimen | Gem + S1 + surgery + S1 (adj) | Surgery + S1 (adj) | Gem regimen (gem+S1/gem/nab-P+gem) + surgery + gem (adj) | Surgery + gem (adj) | FOLFIRINOX + surgery | Surgery | NACRT + surgery + gem (adj) | Surgery + gem (adj) | FOLFIRINOX + surgery | FOLFIRINOX + surgery |
| mOS (months) | 36.72 | 26.65 | 41.6 | 23.3 | 37.7 | 25.1 | 17.1 | 13.7 | 22.2 | 24.2 |
| HR | 0.74 | |||||||||
| mDFS (months) | 29.1 | 13.7 | 9.9 | 7.9 | 18 | |||||
| HR | 0.23 | |||||||||
| R0 (%) | 80.8 | 79.04 | 78 (R tot) | 63 | 31 | 83.9 | 27 | |||
BRPC = borderline resectable pancreatic cancer; LAPC = locally advance pancreatic cancer; RPC = resectable pancreatic cancer; Gem = gemcitabine; nab-P = nab-paclitaxel; FOLFIRINOX = combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin; NACRT= neoadjuvant chemoradiotherapy with weekly gemcitabine.